General
Preferred name
BROMAZEPAM
Synonyms
RO 5-3350 ()
RO-5-3350 ()
NSC-140669 ()
Lexotan ()
Lexatin ()
Bromazepam civ ()
Lexotanil ()
Lectopam ()
P&D ID
PD009477
CAS
1812-30-2
Tags
available
drug
First approval
1974
Drug indication
Anxiety
Anxiety disorder
Panic attacks
Drug Status
investigational
illicit
approved
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
Bromazepam binds to the GABA-A receptor producing a conformational change and potentiating its inhibitory effects. Other neurotransmitters are not influenced.
PHARMACODYNAMICS
Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence. According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
10
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
30
Molecular Weight
315.0
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
2
cLogP
2.63
TPSA
54.35
Fraction CSP3
0.07
Chiral centers
0.0
Largest ring
7.0
QED
0.88
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Therapeutic Class
Hypnotics and Sedatives
Source data

